Attacking Alzheimer's Disease and Neurodegeneration by Improving 
AXONAL TRANSPORT

We enhance the FLOW of Information Along the Information Highway of Nerve Cells

 

WE ARE DEVELOPING DRUGS FOR ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE, INCLUDING THE ORPHAN INDICATION DEMENTIA AND ALZHEIMER’S IN DOWN SYNDROME

Our novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population

5.8M

Americans with Alzheimer's Disease

Increase in Alzheimer diagnoses by 2060

3x

Failed drug development attempts since 1998

130

The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that hypothesis looks less credible than ever. 

Raymond J. Tesi STAT News April 30, 2019

Aducanumab's failure puts pressure on field to look beyond amyloid

Ned Pagliarulo March 22, 2019

ALZHEIMER'S DISEASE DRUG FAILURE

Amyloid Plaque and Aβ is NOT The Only Answer

After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

Neurotoxic proteins reduce axonal transport and cause a 
TOXIC CASCADE 

Impaired axonal transport lowers levels of neurotransmitters and neurotrophic proteins leading to nerve cell death.

We Are Working to
REVERSE

the Toxic Cascade

Plaques, tangles, and Lewy bodies represent the end stage of neurodegeneration. The disease STARTS with impaired axonal transport caused by high-levels of neurotoxic proteins.

ANNOVIS BIO
1055 Westlakes Drive
Suite 300

Berwyn, PA 19312

Website Design by 

Lamnia-Logo-White-PNG.png

(c) 2019 Annovis Bio, All Rights Reserved